Subject Impression Data for STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

Nasal Safety Data of STS101 From the Ongoing Phase 3 Open-Label ASCEND Study 

STS101 Demonstrates Rapid, Consistent Absorption and Sustained Target Plasma Concentrations of Dihydroergotamine (DHE) With Low Variability 

Relationship of Dihydroergotamine (DHE) Pharmacokinetic Parameters and Clinical Efficacy and Systemic Side Effects 

Long-term safety and tolerability of STS101, a novel investigational dihydroergotamine nasal powder: initial data from the ASCEND study 

Cardiovascular safety of STS101, a novel investigational DHE nasal powder product: initial data from the ASCEND study 

Pharmacokinetics and safety of STS101, a novel investigational DHE powder drug-device combination in healthy subjects 

Pharmacokinetic comparison of STS101 (A novel investigational DHE nasal powder) with liquid nasal spray, injectable, and oral inhaled DHE formulations 

Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception

The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications